Last reviewed 2026-04-23 · How we verify

D086

D086 is a small molecule that acts as a selective inhibitor of the enzyme responsible for its mechanism.

D086 is a small molecule that acts as a selective inhibitor of the enzyme responsible for its mechanism. Used for Hypertension.

At a glance

Mechanism of action

The exact mechanism of action of D086 is not well understood, but it is believed to involve the inhibition of a specific enzyme involved in the disease process. This inhibition leads to a decrease in the disease symptoms.

Approved indications

• Hypertension

Common side effects

• Headache
• Dizziness
• Nausea

Key clinical trials

• A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia (PHASE3)
• Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers (PHASE1)
• Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers (PHASE1)
• Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet (PHASE3)
• Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337 (PHASE1)
• Pharmacokinetics and Safety Profile of CKD-333 (PHASE1)
• Pharmacokinetic Drug-drug Interaction of CKD-330 and D086 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• D086 CI brief — competitive landscape report
• D086 updates RSS · CI watch RSS
• Chong Kun Dang Pharmaceutical portfolio CI